Ampersand Biomedicines

Boston, United States

Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.

$65.0M raised

Mar 2025

Series B

Biopharma Biotechnology Medical Therapeutics

Top Investors

Eli LillyFlagship Pioneering

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Ampersand Biomedicines

How much funding has Ampersand Biomedicines raised?

Ampersand Biomedicines has raised $65.0M in total funding. The most recent round was Series B. The last funding was announced in March 2025.

Who are Ampersand Biomedicines's investors?

Ampersand Biomedicines's investors include Eli Lilly, Flagship Pioneering.

Where is Ampersand Biomedicines headquartered?

Ampersand Biomedicines is headquartered in Boston, United States.

What does Ampersand Biomedicines do?

Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.

What stage is Ampersand Biomedicines at?

Ampersand Biomedicines is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 19, 2025.

MLA

"Ampersand Biomedicines — Funding & Investors." VCBacked, March 19, 2025, https://www.vcbacked.co/company/ampersand-biomedicines. Accessed June 3, 2026.

APA

VCBacked. (2025). Ampersand Biomedicines — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/ampersand-biomedicines

Wikipedia (cite web)

{{cite web |title=Ampersand Biomedicines — Funding & Investors |url=https://www.vcbacked.co/company/ampersand-biomedicines |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 19, 2025.